Linked Life Data

7476886

Source:http://linkedlifedata.com/resource/pubmed/id/7476886

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7476886rdf:typepubmed:Citationlld:pubmed
pubmed-article:7476886lifeskim:mentionsumls-concept:C0031640lld:lifeskim
pubmed-article:7476886lifeskim:mentionsumls-concept:C0021467lld:lifeskim
pubmed-article:7476886lifeskim:mentionsumls-concept:C0021469lld:lifeskim
pubmed-article:7476886lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:7476886lifeskim:mentionsumls-concept:C0439596lld:lifeskim
pubmed-article:7476886pubmed:issue4lld:pubmed
pubmed-article:7476886pubmed:dateCreated1995-11-29lld:pubmed
pubmed-article:7476886pubmed:abstractTextProstaglandin E2 produces a transient increase in the intracellular concentration of cAMP in a human promonocytic cell line (U937). The temporal pattern consists of a rapid increase followed by a gradual decline to a new steady state. The decline phase coincides with an increase in the activity of a high affinity form of cAMP phosphodiesterase (PDE). Immunoprecipitation with specific antibodies revealed that the activated enzyme is a variant of PDE-4D. To confirm this observation, three isoforms of human PDE-4 (A, B, and D) were cloned and expressed in Sf9 cells with recombinant baculovirus infection. The activity of only one of the isoforms (PDE-4D3) increased after incubation with the catalytic subunit of protein kinase A and Mg-ATP. Hydrolytic activity of human PDE-4D3 was dependent on Mg2+. Before phosphorylation, the concentration-response curve for Mg2+ was biphasic and ranged from 0.1 to 100 mM. Phosphorylation of PDE-4D3 by protein kinase A produced a monophasic Mg2+ response curve (0.5 Vmax = 0.2 mM). Phosphorylation of PDE-4D3 increased the sensitivity of the enzyme to inhibition by RS-25344 (approximately 100-fold) and RS-33793 (approximately 330-fold). Thus, phosphorylation of PDE-4D3 induces an apparent conformation change that increases maximum velocity and sensitivity to inhibition by some analogues of nitraquazone. These observations provide the basis for a novel pharmacological strategy that targets an activated form of PDE in human leukocytes. Selective PDE-4D3 inhibitors may have useful anti-inflammatory properties with fewer adverse side effects than other PDE-4 inhibitors.lld:pubmed
pubmed-article:7476886pubmed:languageenglld:pubmed
pubmed-article:7476886pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:citationSubsetIMlld:pubmed
pubmed-article:7476886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7476886pubmed:statusMEDLINElld:pubmed
pubmed-article:7476886pubmed:monthOctlld:pubmed
pubmed-article:7476886pubmed:issn0026-895Xlld:pubmed
pubmed-article:7476886pubmed:authorpubmed-author:AlvarezRRlld:pubmed
pubmed-article:7476886pubmed:authorpubmed-author:WilhelmRRlld:pubmed
pubmed-article:7476886pubmed:authorpubmed-author:YangDDlld:pubmed
pubmed-article:7476886pubmed:authorpubmed-author:ContiMMlld:pubmed
pubmed-article:7476886pubmed:authorpubmed-author:SheltonE RERlld:pubmed
pubmed-article:7476886pubmed:authorpubmed-author:SettiGGlld:pubmed
pubmed-article:7476886pubmed:authorpubmed-author:FISETL GLGlld:pubmed
pubmed-article:7476886pubmed:issnTypePrintlld:pubmed
pubmed-article:7476886pubmed:volume48lld:pubmed
pubmed-article:7476886pubmed:ownerNLMlld:pubmed
pubmed-article:7476886pubmed:authorsCompleteYlld:pubmed
pubmed-article:7476886pubmed:pagination616-22lld:pubmed
pubmed-article:7476886pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:meshHeadingpubmed-meshheading:7476886-...lld:pubmed
pubmed-article:7476886pubmed:year1995lld:pubmed
pubmed-article:7476886pubmed:articleTitleActivation and selective inhibition of a cyclic AMP-specific phosphodiesterase, PDE-4D3.lld:pubmed
pubmed-article:7476886pubmed:affiliationInstitute of Pharmacology, Syntex Discovery Research, Palo Alto, California 94304, USA.lld:pubmed
pubmed-article:7476886pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7476886lld:pubmed